Activators & Inhibitors

Utomilumab (PF 05082566) is a humanized IgG2 antibody targeting the T-cell co-stimulatory receptor 4-1BB/CD137 and a 4-1BB/CD137 agonist.Utomilumab has antitumor activity and may be used in the study of patients with advanced malignancies.

Brentuximab is a chimeric antibody targeting CD30 and is a naked antibody to Brentuximab vedotin.Brentuximab has antitumor activity and may be used to study relapsed or refractory Hodgkin's lymphoma.

Sarilumab （SAR-153191）is a potent interleukin-6 IL-6 receptor antagonist and a human immunoglobulin G1 monoclonal antibody. Sarilumab inhibits IL-6-mediated signaling and reduces inflammation.Sarilumab is used for the prevention and treatment of rheumatoid arthritis.

Teplizumab (MGA-031) is a humanized monoclonal antibody against CD3 that slows the loss of beta cell function.Teplizumab is used to treat type 1 diabetes.

Risankizumab (BI 655066) is a humanized IgG monoclonal antibody (Kd <10 pM) targeting the IL-23 p19 subunit. Risankizumab inhibits IL-17 production induced by human IL-23 in mouse splenocytes with an IC50 value of 2 pM.Risankizumab is used for the prevention and treatment of immune and inflammatory disorders such as psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis, and erythrodermic psoriasis.

Brodalumab (AMG 827) is a human monoclonal antibody targeting interleukin 17 receptor (IL-17R) IgG2, often used as an immunosuppressant in the treatment of psoriasis and psoriasis.

Onartuzumab (MetMAb) is a humanized anti-tyrosine kinase c-MET monovalent monoclonal antibody.Onartuzumab has antitumor activity with inhibitory effects on HGF binding, receptor phosphorylation, and signal transduction.

Xentuzumab (BI836845) is a recombinant monoclonal antibody to humanised IGF ligand that inhibits IGF1 and IGF2 growth-promoting signalling and inhibits AKT activation for the study of solid tumours.

Patritumab (U3-1287) is an anti-HER3 monoclonal antibody with potential antitumor activity and inhibits phosphorylation of EGFR, HER2, HER3, ERK, and AKT.Patritumab promotes apoptosis and inhibits proliferation in non-small cell lung cancer.